CalciMedica Shares Collapse After Independent Review Halts AKI Phase 2 Trial
CalciMedica Inc. (NASDAQ:CALC) saw its stock fall roughly 80% on Wednesday after an Independent Data Monitoring Committee recommended stopping the Phase 2 KOURAGE trial for acute kidney injury due to safety concerns. The company said no deaths were attributed to the study drug and no serious adverse events required expedited FDA reporting. CalciMed…